Vectorious Medical Technologies
Miniature Implant for Left Atrial Monitoring
Company Overview
Snapshot
Founded in October 2011 by Eyal Orion, Vectorious Medical Technologies operates with 51–200 employees. The company secured a breakthrough device designation for its left atrial pressure monitoring device in November 2020. It was acquired by Edwards Lifesciences in September 2025.
Business overview
Vectorious Medical Technologies develops an in-heart microcomputer designed to monitor the left atrium pressure, enabling optimal treatment for heart disease patients. Its core product, the V-LAP sensory implant, is a digital, wireless, battery-less device that provides actionable feedback through high-resolution waveform morphology from within the heart. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare, serving patients and healthcare providers globally.
Strategic signal
In September 2025, Vectorious Medical Technologies was acquired by Edwards Lifesciences for $497 million. This acquisition signals strong validation of Vectorious's innovative in-heart monitoring technology and its potential to significantly impact heart disease management, providing a clear exit for investors and integrating its solution into a larger medical technology portfolio.
Log in to access full profile ›Company Intelligence Q&A
- What was the most significant corporate development for Vectorious Medical Technologies?
- Vectorious Medical Technologies was acquired by Edwards Lifesciences for $497 million in September 2025.
- What is the primary technology developed by Vectorious Medical Technologies?
- Vectorious Medical Technologies has developed the V-LAP sensory implant, an in-heart microcomputer that monitors the heart's left atrium pressure to optimize treatment for heart disease patients.
- When did Vectorious Medical Technologies receive a breakthrough device designation?
- In November 2020, Vectorious Medical Technologies was granted a breakthrough device designation for its left atrial pressure monitoring device.
- What was a key finding from the VECTOR-HF I study?
- In May 2022, Vectorious announced that the VECTOR-HF I study confirmed the safety and accuracy of its V-LAP In-Heart Sensor for left atrial pressure management of heart failure.